Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma

• DOI: 10.1016/j.lrr.2022.100319
• Publication Date: 2022-04-28T17:09:23Z
• Authors: Suheil Albert Ata...; Michael J. Robertson
• Keywords: 0301 basic medicine; Antibody drug conjugates; 03 medical and health sciences; Lymphoma; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Monoclonal antibodies; Immunotherapy; Bispecific antibodies; RC254-282; Article; 3. Good health

The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of monoclonal antibodies that act in different ways against non-Hodgkin lymphoma tumor cells. These could directly target a single surface antigen resulting in various ways of tumor cells toxicity and killing. Other forms of monoclonal antibodies include antibody-drug conjugates and bispecific antibodies. The role of therapeutic monoclonal antibodies in the treatment of lymphoma will be reviewed, highlighting their mode of action, clinical efficacy, and side effects.